Influenza Medication Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL INFLUENZA MEDICATION INDUSTRY

2.1 Summary about Influenza Medication Industry

2.2 Influenza Medication Market Trends

2.2.1 Influenza Medication Production & Consumption Trends

2.2.2 Influenza Medication Demand Structure Trends

2.3 Influenza Medication Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Zanamivir

4.2.2 Oseltamivir phosphate

4.2.3 Peramivir

4.2.4 Other Influenza Medication

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 adult

4.3.2 kids

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Zanamivir

5.2.2 Oseltamivir phosphate

5.2.3 Peramivir

5.2.4 Other Influenza Medication

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 adult

5.3.2 kids

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Zanamivir

6.2.2 Oseltamivir phosphate

6.2.3 Peramivir

6.2.4 Other Influenza Medication

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 adult

6.3.2 kids

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Zanamivir

7.2.2 Oseltamivir phosphate

7.2.3 Peramivir

7.2.4 Other Influenza Medication

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 adult

7.3.2 kids

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Zanamivir

8.2.2 Oseltamivir phosphate

8.2.3 Peramivir

8.2.4 Other Influenza Medication

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 adult

8.3.2 kids

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Zanamivir

9.2.2 Oseltamivir phosphate

9.2.3 Peramivir

9.2.4 Other Influenza Medication

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 adult

9.3.2 kids

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Bristol-Myers Squibb

10.1.2 AstraZeneca

10.1.3 Eli Lilly

10.1.4 Roche

10.1.5 GSK

10.1.6 Novartis

10.1.7 Pfizer

10.1.8 Sanofi

10.1.9 Bayer

10.1.10 Celgene

10.1.11 Seqirus

10.2 Influenza Medication Sales Date of Major Players (2017-2020e)

10.2.1 Bristol-Myers Squibb

10.2.2 AstraZeneca

10.2.3 Eli Lilly

10.2.4 Roche

10.2.5 GSK

10.2.6 Novartis

10.2.7 Pfizer

10.2.8 Sanofi

10.2.9 Bayer

10.2.10 Celgene

10.2.11 Seqirus

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Influenza Medication Product Type Overview

2.Table Influenza Medication Product Type Market Share List

3.Table Influenza Medication Product Type of Major Players

4.Table Brief Introduction of Bristol-Myers Squibb

5.Table Brief Introduction of AstraZeneca

6.Table Brief Introduction of Eli Lilly

7.Table Brief Introduction of Roche

8.Table Brief Introduction of GSK

9.Table Brief Introduction of Novartis

10.Table Brief Introduction of Pfizer

11.Table Brief Introduction of Sanofi

12.Table Brief Introduction of Bayer

13.Table Brief Introduction of Celgene

14.Table Brief Introduction of Seqirus

15.Table Products & Services of Bristol-Myers Squibb

16.Table Products & Services of AstraZeneca

17.Table Products & Services of Eli Lilly

18.Table Products & Services of Roche

19.Table Products & Services of GSK

20.Table Products & Services of Novartis

21.Table Products & Services of Pfizer

22.Table Products & Services of Sanofi

23.Table Products & Services of Bayer

24.Table Products & Services of Celgene

25.Table Products & Services of Seqirus

26.Table Market Distribution of Major Players

27.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

28.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

29.Table Global Influenza Medication Market Forecast (Million USD) by Region 2021f-2026f

30.Table Global Influenza Medication Market Forecast (Million USD) Share by Region 2021f-2026f

31.Table Global Influenza Medication Market Forecast (Million USD) by Demand 2021f-2026f

32.Table Global Influenza Medication Market Forecast (Million USD) Share by Demand 2021f-2026f